ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
CordenPharma is adding lipid purification capacity at its facility in Boulder, Colorado, in response to mounting demand for lipid nanoparticles needed to make messenger RNA–based COVID-19 vaccines. The German drug services firm manufactures cationic lipids, pegylated lipids, distearoylphosphatidylcholine phospholipids, and plant-based cholesterol stabilizers—all used in vaccines. The firm expects the expansion to accelerate lipids delivery by July. The expansion is the latest in a series of investments by CordenPharma, which supplies lipid excipients to Moderna.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X